Claire Panosian Dunavan writes there is plenty of blame to go around when it comes to the flawed distribution of malaria-fighting drugs to developing countries, particularly in Africa. Citing the recent decision by the pharmaceutical giant Sanofi-Aventis to destroy an effective anti-malarial drug due to short shelf life and export complications, the professor of health and infectious diseases at the University of California, Los Angeles, argues that better distribution methods may be found as new health initiatives flow into Africa.